

UCSF

UC San Francisco Previously Published Works

Title

Effect of reducing the nicotine content of cigarettes on cigarette smoking behavior and tobacco smoke toxicant exposure: 2-year follow up.

Permalink

<https://escholarship.org/uc/item/8gg3s3gj>

Journal

Addiction (Abingdon, England), 110(10)

ISSN

0965-2140

Authors

Benowitz, Neal L
Nardone, Natalie
Dains, Katherine M
et al.

Publication Date

2015-10-01

DOI

10.1111/add.12978

Peer reviewed

Effect of reducing the nicotine content of cigarettes on cigarette smoking behavior and tobacco smoke toxicant exposure: 2-year follow up

Neal L. Benowitz^{1,2}, Natalie Nardone¹, Katherine M. Dains¹, Sharon M. Hall³, Susan Stewart⁴, Delia Dempsey¹ & Peyton Jacob III^{1,3}

Division of Clinical Pharmacology and Experimental Therapeutics, Medical Service, San Francisco General Hospital Medical Center, San Francisco, CA, USA,¹ Departments of Medicine and Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA,² Department of Psychiatry, University of California, San Francisco, CA, USA³ and Department of Public Health Sciences, University of California Davis, San Francisco, CA, USA⁴

ABSTRACT

Background and Aims A broadly mandated reduction of the nicotine content (RNC) of cigarettes has been proposed in the United States to reduce the addictiveness of cigarettes, to prevent new smokers from becoming addicted and to facilitate quitting in established smokers. The primary aim of this study was to determine whether following 7 months of smoking very low nicotine content cigarettes (VLNC), and then returning to their own cigarettes, smokers would demonstrate persistently reduced nicotine intake compared with baseline or quit smoking. **Methods** In a community-based clinic 135 smokers not interested in quitting were randomized to one of two groups. A research group smoked their usual brand of cigarettes, followed by five types of research cigarettes with progressively lower nicotine content, each for 1 month, followed by 6 months at the lowest nicotine level (0.5 mg/cigarette) (53 subjects) and then 12 months with no intervention (30 subjects completed). A control group smoked their usual brand for the same period of time (50 subjects at 6 months, 38 completed). Smoking behavior, biomarkers of nicotine intake and smoke toxicant exposure were measured. **Results** After 7 months smoking VLNC, nicotine intake remained below baseline (plasma cotinine 149 versus 250 ng/ml, $P < 0.005$) with no significant change in cigarettes per day or expired carbon monoxide (CO). During the 12-month follow-up, cotinine levels in RNC smokers rose to baseline levels and to those of control smokers. Quit rates among RNC smokers were very low [7.5 versus 2% in controls, not significant). **Conclusions** In smokers not interested in quitting, reducing the nicotine content in cigarettes over 12 months does not appear to result in extinction of nicotine dependence, assessed by persistently reduced nicotine intake or quitting smoking over the subsequent 12 months.

Keywords Addiction, biomarkers, cigarette smoking, cotinine, drug dependence, nicotine, reduction.

Correspondence to: Neal L. Benowitz, Division of Clinical Pharmacology and Experimental Therapeutics, University of California, San Francisco, Box 1220, San Francisco, California 94143-1220. E-mail: neal.benowitz@ucsf.edu

Submitted 25 November 2014; initial review completed 9 February 2015; final version accepted 30 April 2015

INTRODUCTION

In 1994 Benowitz & Henningfield proposed the idea of federal regulation of the nicotine content of cigarettes such that it would be reduced over time [1]. When nicotine levels became very low, cigarettes would be much less addictive. As a result, fewer young people would become addicted adult smokers, and currently addicted smokers would find it easier to quit smoking. The regulatory authority to promulgate such a public health intervention was provided by the Family Smoking Prevention and Tobacco Control Act, passed in 2009 [2]. Although it precludes

'reducing nicotine to zero', it permits the US Food and Drug Administration (FDA) to set standards for cigarette nicotine content that would prevent them from causing addiction.

We previously reported the first 6 months of a 2-year study of smoking behavior and tobacco smoke toxicant exposure with the progressive reduction of nicotine content in cigarette tobacco [3]. The focus of that paper was nicotine intake and biomarkers of tobacco toxicant exposure after 6 months of progressive tapering, compared to a control group, who smoked their usual brand throughout the study. Those randomized to reduced nicotine content (RNC) cigarettes decreased their daily nicotine intake

on average by 70%, without significant changes in the number of cigarettes smoked per day or in tobacco toxicant exposure biomarkers.

The present analysis focuses on the last 18 months of that study, during which RNC smokers smoked the lowest nicotine content cigarette for 6 months, followed by a year without provision of cigarettes. We examined the hypotheses that (1) once their daily intake of nicotine had been lowered following tapering (over 6 months), the level of nicotine dependence of smokers of RNC would be decreased such that they would be satisfied to continue smoking very low nicotine content cigarettes without difficulty (for an additional 6 months) and (2) once they stopped smoking RNC cigarettes, their intake of nicotine from conventional cigarettes would remain below their baseline or they would quit smoking because they had become less nicotine-dependent.

METHODS

Subjects

Subjects were recruited by newspaper advertisements, radio advertisements and flyers looking for smokers interested in a reduced nicotine cigarette study, and not interested in quitting smoking in the next 6 months. Inclusion criteria included being aged between 18 and 70 years, healthy, smoking 10 or more cigarettes per day (CPD) for the past year and having screening expired carbon monoxide (CO) levels of 25 parts per million (p.p.m.) or saliva cotinine levels of 100 ng/ml or more. Exclusion criteria included pregnancy or lactation, psychiatric conditions such as current major depression or a history of schizophrenia, current use of smokeless tobacco, pipes or cigars and alcohol or drug dependence.

A total of 238 subjects were screened for study participation. The participant flow diagram is provided in Fig. 1.




Figure 1 Participant flow diagram

Of those screened, 139 subjects met inclusion criteria and completed the baseline assessment, and 135 subjects were randomized to RNC or control groups in blocks of 10 subjects. The tapering phase of the study was completed by 53 RNC subjects and 50 control subjects.

The non-completing participants in months 6–24, the time interval which is the current focus, are described in the results and Fig. 1. Eight RNC subjects dropped out while smoking the lowest nicotine content cigarettes due to product dissatisfaction. A total of 38 subjects in the control group and 30 subjects in the RNC group completed the 24 months of the study.

Study protocol

This was a 2-year, two-arm, randomized, unblinded study in which all subjects smoked their usual brand of cigarette for a baseline period of 2 weeks, and were then assigned randomly to a research or control arm. The research (RNC) group smoked five levels of progressively lower nicotine content cigarettes, the first four levels being smoked for 4 weeks each. The lowest nicotine content cigarette was smoked for 7 months. The control group smoked their usual brand of cigarettes for 12 months. Thereafter, all subjects were followed for an additional year after returning to smoking cigarettes of their own choosing (or quitting). Cigarettes were provided at no cost for the first 12 months for both RNC and control subjects. No cigarettes were provided during the 12 months of follow-up. If subjects expressed interest in quitting or had quit smoking between visits, they were given the Clearing the Air and the American Cancer Society Smart Move stop smoking manuals.

Subjects were studied in a community-based research clinic. Visits were scheduled biweekly for the first 6 months, monthly for the next 6 months, and then at 15, 18 and 24 months. Subjects were instructed to smoke their cigarettes as desired, but when smoking the research cigarettes not to smoke any other type of cigarette or use other forms of tobacco or nicotine medications. RNC subjects were encouraged to report non-study cigarette use to the research staff, without penalty. At each visit expired CO, body weight and blood pressure were measured; blood and urine samples were collected; and questionnaires were administered. Subjects were paid for participation. Written informed consent was obtained from each subject. The study was approved by the Institutional Review Board at the University of California San Francisco.

Cigarettes

Philip Morris Tobacco Company manufactured the RNCs by blending very low nicotine tobacco with tobacco containing higher amounts of nicotine. The paper and filters and weight of tobacco in the research cigarettes were

similar to a Marlboro cigarette. The nicotine content per cigarette was targeted to be 12, 8, 4, 2 and 1 mg, to allow for a 50% nicotine reduction in nicotine dose at each step between 8 and 1 mg. These five levels were selected so at the end of tapering, the maximum systemic nicotine intake would be expected to be 0.2 mg per cigarette or less, based on bioavailability calculations that have been described previously [3]. The actual nicotine contents of the cigarettes, measured in our laboratory, were 10.3, 6.5, 3.9, 1.7 and 0.5 mg. The lowest level of nicotine availability was based on an estimate of the threshold level of nicotine to maintain nicotine addiction. Characteristics of research cigarettes have been published previously [3]. The research cigarettes were packaged in plain packs. Subjects were told that the research cigarettes would contain different levels of nicotine than their usual brand. Menthol-flavored RNCs were not available, so subjects who typically smoked menthol cigarettes switched to non-menthol cigarettes.

Questionnaires

Questionnaires administered at each visit included a report of smoking behavior during the previous 4 weeks, profile of mood states (POMS) [4], the Minnesota Nicotine Withdrawal Scale (MNWS) [5], the Fagerström Test for Cigarette Dependence (FTCD) [6] and a Cigarette Acceptance questionnaire. The Cigarette Acceptance questionnaire uses items that cluster into seven scales: satisfaction, similarity to usual brand, psychological reward, aversion, respiratory sensations, craving and perceived strength [7]. The cigarette acceptance scale was administered only for 12 months while subjects were smoking RNC cigarettes. A smoking-specific Self-efficacy questionnaire [8], the Stages of Change questionnaire [9] and the Center for Epidemiologic Studies–Depression (CES-D) scale were administered at baseline and 3, 6, 12 and 24 months [10]. We used the Stages of Change Questionnaire to assess movement towards quitting smoking, including pre-contemplation (no intention to quit within the next 6 months), contemplation (seriously considering quitting in the next 6 months) and preparation. The Self-Efficacy questionnaire (SLFE) is a 14-item instrument, measured on a 10-point Likert scale, asking about the confidence of smokers and their ability to resist smoking in various high risk situations [8]. Quitting was assessed as 7 day point prevalence abstinence, meaning a self-report of smoking no cigarettes in the past 7 days. These reports were confirmed biochemically as plasma cotinine concentration of < 14 ng/ml or, if taking nicotine replacement medication, an expired CO concentration of < 5 p.p.m.

Analytical chemistry

Plasma samples were assayed for concentrations of nicotine and cotinine by gas chromatography [11,12].

Urine samples were assayed for concentrations of 4-(methylnitrosamino)-1-(3) pyridyl-1-butanol (NNAL), the metabolite of the carcinogenic tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3)pyridyl-1-butanone (NNK) and metabolites of four polycyclic aromatic hydrocarbons (PAH) found in tobacco smoke. NNAL and PAH metabolites are biomarkers of exposure to common tobacco smoke carcinogens. Urine concentrations of NNAL (free + conjugated) and PAH metabolites, including 2-naphthol, 1, 2 and 3+4 hydroxyphenanthrenes, 1-hydroxypyrene and 2-hydroxyfluorene, were measured by liquid chromatography/tandem mass spectrometry [13,14]. Urine PAHs were measured to 12 months, but not beyond.

Statistical analysis

Statistical analysis was based on the 103 subjects (53 RNC and 50 controls) who completed the first 6 months of the study. Because measurements for each individual were correlated over time, a repeated-measures model was constructed for each of the major variables. A mixed-effects regression analysis was conducted with Proc Mixed in SAS (version 9.3). Measurements at baseline, 6, 12, 18 and 24 months were modeled as a function of time and study arm, using time \times study arm interactions to assess intervention effects. Models were examined with and without adjustment for age, gender, race/ethnicity and baseline use of menthol cigarettes. Unadjusted analyses are presented in the tables, and the few differences that occurred between adjusted and unadjusted analyses are mentioned in the text. Differences in mean values were estimated for each pair of time-points within each study arm, as well as

the difference between the study arms with respect to each time-point comparison; statistical significance was assessed at the 0.05 level (two-sided) using the Bonferroni adjustment to account for 10, six or three pairwise comparisons at five, four or three time-points, respectively. Variable values for urine total NNAL and PAH metabolites and time to first cigarette were log-transformed to achieve approximate normality, and the analyses were conducted on the logged values. The models used observations at all available time-points for participants who completed the first 6 months of the study; for those who dropped out after 6 months, data collected at all study visits during the individual's participation were included in the analyses. Means or geometric means with 95% confidence intervals (CI) were computed at each time-point for control participants, RNC participants and RNC participants who complied with the study protocol. The study arms were compared with respect to stages of change (pre-contemplation versus all others) at each time-point using χ^2 tests; dropouts were assumed to be in pre-contemplation. There were relatively few menthol cigarette smokers as baseline (10–11%), but because menthol RNC were not available, we also performed the analyses excluding menthol smokers. Most of the results did not differ with and without menthol smokers; the few differences are mentioned in the results.

RESULTS

Subject retention

Demographic and smoking behavior characteristics are shown in Table 1. The time-course and reasons for the dropouts are summarized in Fig. 1 and their demographic

Table 1 Demographic characteristics by group (mean, 95% confidence interval).

Characteristic	Control group (n = 50)	Research group (n = 53)	Dropouts post-6 months (n = 35)
Age, years	37.4 (34.4,41.0)	36.6 (33.4,39.2)	34.1 (33.4,34.8)
Gender			
Male	31	25	20
Female	19	28	15
Race/ethnicity (%)			
Caucasian	70	70	71
AA	8	8	6
Asian	10	6	9
Other/mixed	12	16	14
BMI	24.8 (24.5,25.0)	26.3 (26.1,26.6)	25.0 (24.0,26.1)
Education, years	15.7 (14.9,16.1)	15.1 (14.6,15.8)	15.7 (14.1, 17.2)
CPD	19.9 (17.9,22.0)	23.4 (21.5,25.4)	23.0 (22.0, 24.0)
Years smoked	21.4 (17.9,24.8)	20.5 (17.5,23.5)	18.2 (18.0,19.0)
Menthol n (%)	5 (10%)	6 (11%)	4(11%)
FTC nicotine (mg)	1.0 (0.9,1.0)	1.0 (0.9,1.0)	1.0 (0.9,1.0)
FTC tar (mg)	11.6 (10.8,12.3)	11.4 (10.6,12.1)	10.7 (10.0, 12.0)
FTCD score	5.5 (4.9,6.2)	5.6 (5.2,6.1)	5.4 (4.0,7.0)

AA = African American; BMI = body mass index; CPD = cigarettes per day; FTC = Federal Trade Commission; FTCD = Fagerström Test for Cigarette Dependence.

Table 2 Smoking behavior and biomarkers of exposure while smoking reduced nicotine cigarettes means.

Characteristic	Baseline (usual)	6 Months (1 mg)	12 Months (1 mg)	18 Months	24 Months	Significant interactions
	Control (n = 55) Research (n = 80)	Control (n = 50) Research (n = 53)	Control (n = 48) Research (n = 37)	Control (n = 40) Research (n = 32)	Control (n = 38) Research (n = 30)	
Cigarettes per day [‡]	20 (18, 22) 23 (21, 25)	22 (19, 25) 20 (17, 23)	21 (18, 23) 22 (18, 25)	17 (14, 20) ^a 17 (14, 21) ^a	16 (14, 19) ^a 13 (9, 17) ^a	6M v. BL, 24M v. BL
Plasma cotinine ng/ml [†]	268 (233, 302) 250 (222, 277)	239 (202, 278) ^a 113 (81, 145) ^a	267 (223, 310) 149 (110, 188) ^a	238 (192, 284) 210 (170, 250) ^b	209 (174, 244) ^a 173 (135, 211) ^c	6M v. BL, 12M v. BL 18M v. 6M, 24M v. 6M 18M v. 12M, 24M v. 12M
Expired CO (p.p.m.) [†]	22 (19, 2) 25 (22, 28)	20 (17, 23) 23 (19, 26)	23 (20, 26) 23 (19, 27)	20 (18, 24) 22 (17, 27)	19 (15, 22) 20 (15, 24)	NS
Urine (pmol/mg creatinine)						
Total NNAL*	1.0 (0.7, 1.3) 1.4 (1.1, 1.7)	0.9 (0.6, 1.2) 0.8 (0.5, 1.1) ^a	0.8 (0.7, 0.9) 0.8 (0.7, 0.9) ^a		0.6 (0.4, 0.7) 0.7 (0.6, 0.09)	6M v. BL
Sum of phenanthrenes*	3.5 (2.8, 4.4) 4.0 (3.3, 4.7)	4.0 (3.3, 4.7) 3.9 (3.1, 4.8)	4.0 (1.1, 7.0) 3.8 (2.0, 6.1)			NS
2-naphthol*	97 (73, 129) 161 (123, 210)	112 (92, 136) 137 (107, 174)	105 (102, 108) 115 (113, 117)			NS
2-hydroxyfluorene*	13 (10, 17) 17 (14, 22)	15 (12, 18) 17 (13, 23)	14 (12, 16) 16 (14, 18)			NS
1-hydroxypyrene*	1.1 (0.9, 1.5) 1.4 (1.1, 1.7)	1.4 (1.1, 1.6) 1.5 (1.2, 1.9)	1.5 (0.6, 3.0) 1.4 (0.4, 3.0)			NS

*Geometric means [95% confidence interval (CI)]; [†]arithmetic means (95% CI); ^asignificantly different from baseline, $P < 0.005$; ^bsignificantly different from 6 months, $P < 0.005$; NNAL = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; CO = carbon monoxide; NS = not significant; p.p.m. = parts per million; 6M = 6 months; 12M = 12 months; 18M = 18 months; 24M = 24 months; BL = baseline; ^csignificantly different from 12 months, $P < 0.005$.

and smoking characteristics are shown in Table 1. There was no significant difference in FTCD or time to first cigarette comparing those who did and did not drop out.

Cigarette consumption and carbon monoxide exposure (Table 2, Figs 2 and 3)

CPD remained unchanged from baseline to 12 months, then decreased significantly in both the RNC and control smokers at 18 and 24 months. Among control subjects, the mean CPD was significantly lower at 18 and 24 months compared to baseline, 6 and 12 months. Among RNC subjects, the mean CPD was significantly lower at 18 months than at baseline and 12 months, and significantly lower at 24 months compared to baseline, 6 and 12 months. After adjustment, the difference between baseline and 18 months was no longer statistically significant. The RNC group had a significantly greater drop in CPD than the control group between baseline versus 6 months and baseline versus 24 months. With exclusion of menthol smokers, the decrease in CPD between 12 and 18 months and the research-control group differences in CPD between baseline and 24 months were no longer




Figure 2 Mean cigarette consumption over 24 months of the study in smokers smoking their usual brand of cigarettes (C) or during progressive reduction of nicotine content of cigarettes (R). The bars represent standard error of the mean




Figure 3 Mean expired carbon monoxide (CO) concentrations over 24 months of the study in smokers smoking their usual brand of cigarettes (C) or during progressive reduction of nicotine content of cigarettes (R). The bars represent standard error of the mean

significant. Expired CO levels remained stable, with no significant change from baseline in either treatment group.

Plasma cotinine concentrations (Fig. 4)

In the RNC group, cotinine concentrations decreased significantly from an average of 250 ng/ml at baseline to 113 ng/ml at 6 months, but increased to 149 ng/ml in those subjects continuing to smoke the lowest nicotine level cigarettes for an additional 6 months. Cotinine levels were significantly lower in RNC versus control smokers at 6 and 12 months. Cotinine concentrations in RNC smokers were significantly higher at 18 versus 6 and 12 months. With exclusion of menthol smokers, the cotinine changes between 6 and 12 months and between 6 and 24 months in RNC were significant.

Total NNAL and PAH metabolites (Table 2)

Total urine NNAL decreased significantly compared to baseline at months 6 and 12 months in RNC subjects, but was not significantly different from baseline values at 24 months. There were no significant changes in NNAL in the control group. Urine PAH levels were similar in RNC and control groups and not significantly different over time.

Body weight and cardiovascular measures (Table 3)

Significant time-related changes occurred in the RNC group with significantly higher body weight at 24 months versus baseline, but this did not differ significantly from controls. The change in body weight in RNC subjects was no longer significant after exclusion of menthol smokers. Subjects in the RNC group had significantly lower hemoglobin concentration at 12 months compared to baseline and at 24 months compared to baseline. After adjustment or exclusion of menthol smokers, changes in hemoglobin concentration were no longer statistically significant. Fibrinogen was significantly higher at 12 months compared




Figure 4 Mean plasma cotinine concentration over 24 months of the study in smokers smoking their usual brand of cigarettes (C) or during progressive reduction of nicotine content of cigarettes (R). The bars represent standard error of the mean

Table 3 Questionnaire and cardiovascular data.

	Baseline (usual)	6 Months (1 mg)	12 Months (1 mg)	18 Months	24 Months
Questionnaires	Control (n = 55) Research (n = 80)	Control (n = 50) Research (n = 53)	Control (n = 48) Research (n = 37)	Control (n = 40) Research (n = 32)	Control (n = 38) Research (n = 30)
FTCD [†]	5.5 (4.9, 6.1) 5.9 (5.5, 6.4)	5.4 (4.6, 6.1) 5.2 (4.7, 6.0)	5.4 (4.7, 6.2) 5.3 (4.6, 6.0)	5.1 (4.4, 5.9) 4.8 (3.9, 5.7)	4.9 (4.1, 5.7) 5.2 (4.3, 6.0)
TFC [†]	21 (12, 29) 24 (8.4, 39)	33 (9.0, 57) 19 (3.2, 35)	34 (12, 56) 26 (10, 40)	51 (1.2, 100) 21 (10, 31)	28 (5.1, 51) 19 (7.7, 30)
MNWS [†]	11 (8.2, 12) 13 (11, 14)	7.6 (6.0, 9.2) 6.9 (5.2, 8.6)	9.1 (7.3, 10) 10 (8.5, 12)	8.2 (6.5, 9.9) 9.4 (7.0, 11)	7.6 (6.0, 9.2) 9.4 (6.6, 12)
CESD [†]	11 (8.5, 12) 13 (10, 15)	11 (8.2, 13) 8.9 (6.6, 11)	13 (10, 15) 14 (10, 17)		12 (8.4, 15) 11 (7.6, 14)
POMS [†]	10 (4.7, 16) 13 (9.1, 17)	6.0 (1.8, 10) 13 (7.4, 17)	9.2 (4.1, 14) 10 (4.5, 15)	6.8 (1.7, 11) 10 (2.8, 16)	6.8 (0.9, 12) 7.3 (0.9, 13)
SLFE [†]	3.5 (3.1, 3.9) 3.6 (3.2, 3.9)	4.0 (3.5, 4.4) 4.1 (3.5, 4.7)	4.2 (3.6, 4.7) 5.0 (4.2, 5.7) ^a		4.6 (3.9, 5.3) 5.6 (4.5, 6.7) ^a
Body weight (kg)*	76 (72, 80) 80 (75, 85)	74 (70, 78) 81 (75, 87)	75 (71, 79) 82 (76, 88)	75 (69, 81) 84 (78, 90)	76 (69, 83) 89 (80, 98) ^a
Systolic blood pressure (mm Hg)*	123 (119, 127) 122 (118, 126)	120 (115, 125) 119 (114, 124)	122 (118, 126) 122 (116, 128)	117 (113, 121) 120 (115, 125)	121 (116, 126) 120 (113, 127)
Heart rate*	83 (78, 86) 81 (78, 84)	79 (75, 83) 79 (76, 82)	81 (77, 85) 83 (80, 86)	80 (76, 84) 83 (79, 87)	79 (75, 83) 79 (74, 84)
WBC count (1000)*	7.5 (6.9, 8.0) 6.9 (6.3, 7.4)	6.8 (6.0, 7.5) 7.3 (6.8, 7.7)	7.3 (6.7, 7.8) 8.0 (7.2, 8.7)		7.5 (6.7, 8.2) 7.1 (6.3, 7.8)
Hemoglobin (%)*	14.7 (14.3, 15.0) 14.5 (14.2, 14.7)	14.4 (14.0, 14.7) 14.3 (14.0, 14.6)	14.6 (14.2, 14.9) 14.2 (13.8, 14.5) ^a		14.4 (13.8, 14.9) 14.0 (13.4, 14.5) ^a
HDL cholesterol (ng/dl)*	53 (48, 58) 54 (51, 58)	54 (49, 59) 53 (49, 57)	52 (47, 57) 53 (49, 57)		53 (46, 60) 52 (46, 58)
Fibrinogen*	278 (252, 304) 281 (264, 298)	281 (256, 306) 301 (279, 323)	291 (267, 315) 338 (307, 369) ^a		288 (258, 318) 320 (289, 351)

FTCD = Fagerström Test for Cigarette Dependence; TFC = time to first cigarette; MNWS = Minnesota Nicotine Withdrawal Scale; CESD = Center for Epidemiological Studies Depression Scale; POMS = Profile of Mood States; SLFE = self-efficacy; HDL = high-density lipoprotein; WBC = white blood cell. *Geometric means [95% confidence interval (CI)]; [†]arithmetic means (95% CI); ^asignificantly different from baseline, $P < 0.005$. No significant interactions were observed.

to baseline. No significant changes in body weight, hemoglobin or fibrinogen were seen in the control group over time. No significant changes were seen in systolic blood pressure, heart rate, white blood cell (WBC) count and high-density lipoprotein (HDL) cholesterol in either group.

Questionnaires (Table 3)

No significant time or group-related changes in total MNWS, total POMS or CES-D were observed. With the exclusion of menthol smokers, MNWS decreased significantly between baseline and 18 months. Responses on the cigarette acceptance questionnaire indicated that RNC were milder, less satisfying, had a lower nicotine effect and were of lesser quality compared to their usual cigarettes. In response to the Self-Efficacy questionnaire, the RNC group reported significantly higher scores at 24 and 12 months compared to their baseline assessment. No significant group-related differences were found.

Regarding Stages of Change, percentages of RNC participants in pre-contemplation throughout the study were: 83% at baseline, 49% at 6 months, 53% at 12 months, 68% at 18 months and 66% at 24 months. For the control group, percentages in the pre-contemplation stage were: 92% at baseline, 86% at 6 months, 60% at 12 months, 60% at 18 months and 70% at 24 months. Significant group differences were found at 6 months, during which more subjects in the RNC group were beyond pre-contemplation compared to control smokers.

No significant changes were observed in FTCD or in time to first cigarette over time or between groups.

Quitting smoking

Quit rates were low in both RNC and control groups, and not significantly different between groups at any time. Point prevalence quitting based on self-reported cigarettes

per day in the RNC group was 5.6% at 6 months, 3.8% at 12 months, 7.5% at 18 months and 11.3% at 24 months. For the control group these rates were 2, 0, 6 and 6% for the same time-points. Biochemically verified quit rates for RNC subjects were 5.6% at 6 months, 3.8% at 12 months, 3.8% at 18 months and 7.5% at 24 months and 2, 2, 6 and 2% for the control group at the same time-points. Only one subject in the RNC group had continued verified abstinence from 6 months to study completion.

Compliance

At the 6- and 12-month visits RNC participants were asked if they had used conventional cigarettes. At 6 months 30% and at 12 months 43% of subjects admitted to smoking other cigarettes in addition to the RNCs. When asked why, participants' reasons included the following: 'just to compare flavor and strength', 'ran out or didn't have research cigarettes' and 'for nicotine'; 25% of those who reported non-compliance stated that it was in the second 6 months of the study.

DISCUSSION

We observed previously that, in smokers who are not planning to quit, gradual reduction of the nicotine content of cigarettes results in reduced intake of nicotine without compensatory over-smoking of cigarettes [3,15]. We hypothesized that with continued smoking of very low nicotine cigarettes, smokers would become less dependent, have less desire for nicotine and would quit smoking. We found that after 7 months of smoking very low RNC, cotinine levels remained significantly lower than baseline. However, from the first to the seventh month of smoking the same very low RNC, cotinine levels increased significantly. There was no change in CPD or exposure to combustion products (CO and PAHs), and no increase in nicotine withdrawal symptoms. Very few subjects quit smoking while receiving very low RNCs.

During the 12-month follow-up when subjects were free to smoke their own cigarettes, cotinine levels in RNC subjects rose to levels similar to control smokers who had never received RNCs. Quitting remained low over the 12-month follow-up period. At 24 months the percentage of smokers in the RNC group who quit smoking was higher than that of the control group, but not significantly so.

Our data suggest that lengthy (6 months) exposure to RNC does not result in the extinction of nicotine dependence, as might be seen in loss of smoking urges, reduction in CPD or increased quitting. One explanation may have been that subjects were able to obtain adequate levels of nicotine to sustain addiction during the period of nicotine reduction. This could be due to subjects obtaining more nicotine than expected by intensive smoking of very low

RNCs, or to supplementing the RNCs with conventional cigarettes.

For many subjects, cotinine levels were higher than expected, given that the nicotine content of the very low nicotine cigarettes was only 5% of that of conventional cigarettes. Based on lack of change in self-reported cigarettes per day, expired CO and PAH metabolite levels, it is unlikely that smokers smoked their research cigarettes exceptionally intensively, as would be necessary to achieve the observed cotinine levels.

A number of subjects (30% at 6 months and 43% at 12 months) reported that they supplemented their reduced nicotine content cigarettes with some conventional cigarettes. We suspect that the higher cotinine levels at 12 compared to 6 months in the RNC smokers was due to non-compliance; that is, smoking some conventional cigarettes in addition to the research cigarettes.

Our study has some important limitations that affect the extrapolation of results to what might be expected with a national nicotine reduction intervention. Our study was conducted in the context of freely available conventional cigarettes. If subjects were not obtaining adequate nicotine from RNCs, they could supplement them easily with conventional cigarettes. In addition, the RNCs were rated as poor quality. Presumably, if major tobacco manufacturers were making RNC cigarettes in a competitive market-place, the cigarettes would be more consumer-acceptable. There was a high non-completion rate, particularly among RNC smokers, related primarily to dissatisfaction with the research cigarettes. Cigarettes were provided at no cost, which may have affected the number of cigarettes smoked. The termination of free cigarettes may explain the decrease in CPD in both groups in the second year of the study. Our subjects were volunteers who were compensated for participation in the study. They understood that this was a time-limited study, and at the end they would be free to return to their usual brand. We excluded subjects with major mental health or substance abuse disorders, who might respond differently to RNC compared to healthy smokers. Finally, while 11% of smokers preferred menthol cigarettes, menthol research cigarettes were not available. We controlled for menthol preference in our data analysis and performed a separate analysis excluding menthol smokers, with few changes in results.

Despite the observation that nicotine reduction did not increase quitting, we did see that RNC smokers expressed greater interest in quitting, as measured using the Stages of Change questionnaire. Our study, as well as others, found no evidence of safety concerns in smokers of RNCs [3,15–17]. Specifically there was no evidence of withdrawal distress or increased depression, and no increases in tobacco smoke toxicants and no adverse changes in selected cardiovascular biomarkers.

The implications of our findings for a possible federally mandated reduction in the nicotine content of cigarettes are as follows. The level of reduction of the nicotine content of cigarettes needed to extinguish nicotine dependence is as yet unknown. We did not observe extinction of dependence in our study, but it is likely that many of our subjects supplemented their nicotine intake from conventional cigarettes. Simply reducing the nicotine content of cigarettes alone may be insufficient to extinguish smoking behavior. A nicotine reduction intervention combined with public education about the reasons for reduction, behavioral support for quitting and/or the easy access to alternative sources of nicotine (such as nicotine medications or electronic cigarettes) may be needed to achieve cessation of cigarette smoking.

Declaration of interests

N.L.B. is a consultant to several pharmaceutical companies that market medications to aid smoking cessation and has served as a paid expert witness in litigation against tobacco companies. S.M.H. has received material support for a clinical trial from Pfizer. The other authors have no conflicts to declare.

Acknowledgements

We thank Dr Faith Allen for data management, Lita Ramos for performing the nicotine and cotinine analyses, Olivia Yturralde for the PAH metabolite analyses and Christopher Havel for the NNAL analyses, and Scott Rostler for editorial assistance. We thank Philip Morris for providing research cigarettes (Philip Morris had no involvement in any aspect of the design of the study or analysis or interpretation of the data). This study was supported by US Public Health Service grants CA78603 from the National Cancer Institute, DA02277, DA12393 and DA016752 from the National Institute on Drug Abuse, and FDA Center for Tobacco Products grant U54031659. Clinical trial registration Clinical Trials No: NCT00264342.

References

1. Benowitz N. L., Henningfield J. E. Establishing a nicotine threshold for addiction. The implications for tobacco regulation. *N Engl J Med* 1994; **331**: 123–5.
2. Family Smoking Prevention and Tobacco Control Act—Public Law No. 111–31. 2009; 2012(5/14).
3. Benowitz N. L., Dains K. M., Hall S. M., Stewart S., Wilson M., Dempsey D., *et al.* Smoking behavior and exposure to tobacco
4. McNair D. M., Lorr M., Doppleman L. F. *Profile of Mood States*. Educational and Industrial Testing Service: San Diego; 1971.
5. Hughes J. R., Hatsukami D. Signs and symptoms of tobacco withdrawal. *Arch Gen Psychiatry* 1986; **43**: 289–94.
6. Heatherton T. F., Kozlowski L. T., Frecker R. C., Fagerstrom K. O. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. *Br J Addict* 1991; **86**: 1119–27.
7. Rose J. E., Westman E. C., Behm F. M., Johnson M. P., Goldberg J. S. Blockade of smoking satisfaction using the peripheral nicotinic antagonist trimethaphan. *Pharmacol Biochem Behav* 1999; **62**: 165–72.
8. Baer J. S., Lichtenstein E. Classification and prediction of smoking relapse episodes: an exploration of individual differences. *J Consult Clin Psychol* 1988; **56**: 104–10.
9. Prochaska J. O., DiClemente C. C. Stages and processes of self-change of smoking: toward an integrative model of change. *J Consult Clin Psychol* 1983; **51**: 390–5.
10. Radloff L. S. The CES-D scale a self-report depression scale for research in the general population. *Appl Psychol Meas* 1977; **1**: 385–401.
11. Jacob P. III, Wilson M., Benowitz N. L. Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids. *J Chromatogr* 1981; **222**: 61–70.
12. Jacob P. III, Yu L., Wilson M., Benowitz N. L. Selected ion monitoring method for determination of nicotine, cotinine and deuterium-labeled analogs: absence of an isotope effect in the clearance of (S)-nicotine-3',3'-d2 in humans. *Biol Mass Spectrom* 1991; **20**: 247–52.
13. Jacob P. III, Wilson M., Benowitz N. L. Determination of phenolic metabolites of polycyclic aromatic hydrocarbons in human urine as their pentafluorobenzyl ether derivatives using liquid chromatography-tandem mass spectrometry. *Anal Chem* 2007; **79**: 587–98.
14. Jacob P. III, Havel C., Lee D. H., Yu L., Eisner M. D., Benowitz N. L. Subpicogram per milliliter determination of the tobacco-specific carcinogen metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in human urine using liquid chromatography-tandem mass spectrometry. *Anal Chem* 2008; **80**: 8115–21.
15. Benowitz N. L., Hall S. M., Stewart S., Wilson M., Dempsey D., III Jacob P. Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette. *Cancer Epidemiol Biomarkers Prev* 2007; **16**: 2479–85.
16. Hitchman S. C., Fong G. T., Borland R., Hyland A. Predictors of smoking in cars with nonsmokers: findings from the 2007 wave of the International Tobacco Control Four Country Survey. *Nicotine Tob Res* 2010; **12**: 374–80.
17. Hatsukami D. K., Hertsgaard L. A., Vogel R. I., Jensen J. A., Murphy S. E., Hecht S. S., *et al.* Reduced nicotine content cigarettes and nicotine patch. *Cancer Epidemiol Biomarkers Prev* 2013; **22**: 1015–24.